{"id":11936,"date":"2026-07-10T11:06:14","date_gmt":"2026-07-10T15:06:14","guid":{"rendered":"https:\/\/www.curingheartdisease.com\/?p=11936"},"modified":"2026-08-25T09:18:46","modified_gmt":"2026-08-25T13:18:46","slug":"lhuile-dolive-est-elle-vraiment-bonne-pour-la-sante","status":"publish","type":"post","link":"https:\/\/www.curingheartdisease.com\/fr\/is-olive-oil-actually-healthy\/","title":{"rendered":"L'huile d'olive est-elle vraiment bonne pour la sant\u00e9 ?"},"content":{"rendered":"

Is Olive Oil Independently Cardioprotective?<\/h3>\n

A Critical Evaluation of Epidemiological, Postprandial, and Clinical Evidence
\nAn evidence-graded review with explicit funding-independence assessment<\/em><\/p>\n

Abstract<\/h3>\n

Background. <\/strong>Extra-virgin olive oil (EVOO) is widely promoted as an independently cardioprotective food. This review evaluates whether isolated olive oil has intrinsic cardioprotective properties, separate from the dietary patterns in which it is consumed and from the industry funding that dominates its evidence base.<\/p>\n

Methods and scope. <\/strong>Primary peer-reviewed sources (prospective cohorts, randomized controlled trials [RCTs], Mendelian randomization [MR], and controlled postprandial studies) were assessed for their reported effect estimates, evidence grade, and funding independence. Because the olive-oil trade sponsors much of the EVOO efficacy literature, each olive-oil study is explicitly classified as independent or industry-influenced, and residual uncertainty is stated in the text rather than smoothed over.<\/p>\n

Findings. <\/strong>Epidemiological associations between olive oil and lower cardiovascular mortality are real but are reproduced in full by other vegetable oils and vanish when olive oil is compared against other plant oils rather than against animal fats. MR finds no causal cardiovascular benefit of circulating monounsaturated fatty acids (MUFAs), the principal olive-oil lipid; the causal signal tracks apolipoprotein B (ApoB) particle number instead. Isolated EVOO acutely impairs endothelial function postprandially, an effect not seen when fat is consumed within a whole-food matrix. Only strict, low-fat, whole-food plant-based (WFPB) patterns excluding all added oils have been shown to arrest and partially reverse angiographic coronary disease. The two major EVOO RCTs (PREDIMED, CORDIOPREV) are both funded by the olive-oil trade body Patrimonio Comunal Olivarero, and PREDIMED was retracted and republished after its randomization was found to be compromised.<\/p>\n

Conclusion. <\/strong>Current independent evidence does not demonstrate a clinically meaningful cardioprotective effect of olive oil beyond the replacement of saturated and trans fats; it is best understood as a comparatively benign substitute for animal fat rather than a food with demonstrated unique intrinsic activity. This is a statement about the absence of convincing evidence, not proof of no effect. No large, fully independent hard-outcome RCT of isolated EVOO exists; this evidentiary gap is itself a central finding.<\/p>\n

A Note on the Evidence Base and Its Funding<\/h3>\n

A recurring difficulty in this field is that nearly every RCT purporting to demonstrate EVOO efficacy on cardiovascular endpoints was funded, in cash or in kind, by the olive-oil trade. PREDIMED and CORDIOPREV both received their intervention oil from Patrimonio Comunal Olivarero<\/em>, an organization whose explicit purpose is to promote Spanish olive-oil exports. [73,76] Industry funding does not by itself invalidate a result, but the systematic<\/strong> entanglement of the entire EVOO-efficacy RCT literature with a single interested party is a legitimate basis for caution. [67,69] Where an independent source supporting the same point exists, it is cited in preference. Where none exists\u2014as is often the case for EVOO\u2014the industry-funded study is retained but flagged in place, and the resulting uncertainty is carried forward into the interpretation. The reader should treat every EVOO efficacy estimate below as provisional to that degree.<\/p>\n

1.\u00a0 Epidemiological Quantification of Olive Oil’s Independent Cardioprotective Efficacy<\/h3>\n

To evaluate whether isolated olive oil possesses independent cardioprotective properties, nutritional epidemiology must be parsed through the lens of replacement dynamics and dietary context. The most comprehensive prospective data in non-Mediterranean cohorts come from the Nurses’ Health Study (NHS) and the Health Professionals Follow-Up Study (HPFS), which together followed 92,383 US men and women free of cardiovascular disease and cancer at baseline for up to 28 years. [1]<\/p>\n

Multivariable-adjusted analyses show that individuals in the highest category of olive oil consumption, defined as more than half a tablespoon per day (>7 g\/day), exhibited a 19% reduction in cardiovascular mortality (hazard ratio [HR] 0.81; 95% confidence interval [CI] 0.75\u20130.87) and a 19% reduction in all-cause mortality (HR 0.81; 95% CI 0.78\u20130.84) versus non-consumers. [1] Higher intake was also associated with an 18% lower risk of coronary heart disease (HR 0.82; 95% CI 0.73\u20130.91), with no significant association for stroke. [2]<\/p>\n

The data further showed a 17% lower risk of cancer mortality (HR 0.83; 95% CI 0.78\u20130.89), a 29% lower risk of neurodegenerative-disease mortality (HR 0.71; 95% CI 0.64\u20130.78), and an 18% lower risk of respiratory-disease mortality (HR 0.82; 95% CI 0.72\u20130.93). [1] A prior draft listed the neurodegenerative CI as 0.78\u20130.89, which is impossible for a point estimate of 0.71 and in fact belongs to the cancer estimate; the corrected interval is 0.64\u20130.78.<\/em><\/p>\n

A separate dose-response meta-analysis of 13 prospective cohorts found each additional 5 g\/day of olive oil associated with a small but significant lower risk of CVD (RR 0.96; 95% CI 0.93\u20130.99) and all-cause mortality (RR 0.96; 95% CI 0.95\u20130.96). [3] This per-increment figure derives from Xia et al., not the Harvard cohorts, and is attributed accordingly.<\/p>\n

The decisive epidemiological test is the head-to-head comparison against other plant oils. <\/strong>Within the same cohorts, replacing 10 g\/day of saturated-fat-dense animal lipids (margarine, butter, mayonnaise, dairy fat) with olive oil was associated with an 8% to 34% lower risk of total and cause-specific mortality. [1] But compared directly with other vegetable oils combined, olive oil showed no statistically significant difference<\/strong> for total CVD, CHD, or stroke. [1,2] On these data the apparent benefit tracks the displacement of atherogenic animal fat rather than any intrinsic property of the olive-oil lipid backbone.<\/p>\n

Residual confounding compounds this. Those with the highest olive oil intake had healthier lifestyles overall (more physical activity, less smoking, more fruit and vegetables), and the authors acknowledged that high olive oil intake may simply mark higher socioeconomic status and overall diet quality. [1]<\/p>\n

1.1\u00a0 The PREDIMED Primary-Prevention Framework<\/h4>\n

PREDIMED randomized 7,447 high-risk Spanish adults to a Mediterranean diet plus free EVOO, a Mediterranean diet plus nuts, or a control (low-fat advice) diet, with 4.8 years’ median follow-up. The EVOO arm showed a lower composite rate of myocardial infarction, stroke, and cardiovascular death (HR 0.69; 95% CI 0.53\u20130.91) versus control, about a 30% relative reduction. [4]<\/p>\n

Two caveats weaken this. First, in secondary analyses the inverse association between baseline EVOO intake and hard events held only within the Mediterranean-randomized groups and was abolished in the low-fat control group\u2014so the value of olive oil appears contingent on the surrounding pattern rather than intrinsic. [4]<\/p>\n

Second, and more seriously, PREDIMED was retracted. <\/strong>A 2017 reanalysis by Carlisle found baseline distributions statistically incompatible with random allocation. [6] The audit found randomization had failed for ~1,588 of 7,447 participants (~21%): household members assigned en masse at one site; a randomization table not used properly at a second; a clinic randomized as a unit at a third. NEJM retracted the 2013 paper in June 2018 and republished a clustering-adjusted reanalysis. [4,5] As it is no longer strictly individually randomized, PREDIMED is best read as a quasi-randomized intervention; NICE had already judged it at serious risk of bias for individual CVD outcomes. [71]<\/p>\n

1.2\u00a0 Secondary Prevention: CORDIOPREV<\/h4>\n

CORDIOPREV randomized 1,002 Spanish coronary patients to a Mediterranean diet rich in EVOO (~35% fat, ~22% MUFA) versus a low-fat diet over 7 years. Recurrent MACE occurred at 28.1 per 1,000 person-years (Mediterranean) versus 37.7 per 1,000 person-years (low-fat), multivariable-adjusted hazard ratios across models ranged from 0.719 (95% CI 0.541\u20130.957) to 0.753 (95% CI 0.568\u20130.998) in favour of the Mediterranean diet, about a 25\u201328% relative reduction (log-rank p = 0.039). [8] 28.1 is the Mediterranean-arm incidence rate per 1,000 person-years, not the percent risk reduction; the CI 0.62\u20130.89 in an earlier draft does not appear in the source and has been replaced with the reported model range.<\/p>\n

The comparator was not a genuine low-fat diet. <\/strong>The control group reduced total fat only to ~32% of calories\u2014short of the clinical <30% threshold and far from the <10\u201315% of the Ornish and Esselstyn reversal trials. Saturated fat was near-identical between arms (~7.9% vs ~7.1%), and the control ate ~10% more protein, mostly animal-source, with fewer legumes, vegetables, and fruits. The benefit may reflect the poor comparator rather than any unique action of EVOO. [8]<\/p>\n

A genetic sub-analysis reinforces this: carriers of the ZPR1 rs964184 risk allele on the Mediterranean diet retained elevated fasting and postprandial triglycerides, whereas those on the low-fat diet normalized them\u2014so for certain genotypes the EVOO-rich pattern was inferior for triglyceride clearance. [9]<\/p>\n

1.3\u00a0 Mendelian Randomization: No Causal Signal for MUFA<\/h4>\n

If oleic acid, the dominant MUFA in olive oil, were directly cardioprotective, genetically higher circulating MUFA should lower risk. Instrumental-variable analyses find no convincing evidence of a causal protective effect of circulating MUFA on CHD, MI, or ischemic stroke. [10] This is a failure to detect an effect rather than positive proof of its absence, but it removes a key plank from the claim of intrinsic benefit. Multivariable MR consistently prioritizes ApoB and LDL particle number as the causal lipid factors, with no independent MUFA signal. [11,12] These genetically anchored, industry-independent data are among the strongest evidence that the cohort associations attributed to olive oil are substantially confounded by consumers’ lifestyle and diet.<\/p>\n

Table 1.\u00a0 Key Studies of Olive Oil and Cardiovascular Outcomes<\/strong><\/h3>\n\n\n\n\n\n\n\n\n\n
Study \/ Cohort<\/strong><\/td>\nPopulation & Design<\/strong><\/td>\nExposure \/ Intervention<\/strong><\/td>\nEffect Estimate (95% CI)<\/strong><\/td>\nKey Caveats<\/strong><\/td>\n<\/tr>\n<\/thead>\n
NHS & HPFS mortality [1]<\/td>\n92,383 US adults; 28-yr prospective cohort<\/td>\nHighest intake (>7 g\/day) vs non-consumers<\/td>\nAll-cause: HR 0.81 (0.78\u20130.84)
\nCVD: HR 0.81 (0.75\u20130.87)<\/td>\n		Benefit fully reproduced by other plant oils; driven by replacing animal fat<\/td>\n<\/tr>\n
NHS & HPFS incident CVD [2]<\/td>\n92,978 US adults; 24-yr prospective cohort<\/td>\nHighest intake vs non-consumers<\/td>\nTotal CVD: HR 0.86 (0.79\u20130.94)
\nCHD: HR 0.82 (0.73\u20130.91)<\/td>\n		No stroke association; no difference vs other plant oils<\/td>\n<\/tr>\n
PREDIMED primary prevention [4]<\/td>\n7,447 high-risk Spanish adults; 4.8-yr quasi-RCT<\/td>\nMedDiet + EVOO vs low-fat advice<\/td>\nComposite MACE: HR 0.69 (0.53\u20130.91)<\/td>\nRETRACTED \/ republished; ~21% mis-randomized; EVOO from olive-oil trade body<\/td>\n<\/tr>\n
CORDIOPREV secondary prevention [8]<\/td>\n1,002 Spanish coronary patients; 7-yr RCT<\/td>\nMedDiet + EVOO vs low-fat diet<\/td>\nRecurrent MACE: HR 0.719\u20130.753 (e.g., 0.541\u20130.957)<\/td>\n\u201cLow-fat\u201d control only ~32% fat; funded by olive-oil trade body<\/td>\n<\/tr>\n
Mendelian randomization [10\u201312]<\/td>\nUK Biobank & GWAS meta-analyses<\/td>\nGenetically determined circulating MUFA (oleic acid)<\/td>\nCHD \/ MI \/ stroke: no causal association<\/td>\nMUFA not causally protective; ApoB is the causal trait<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Green shading = independent evidence supporting the skeptical thesis. Red shading = industry-funded EVOO efficacy RCTs (retained with caveat; see text).<\/em><\/p>\n

1.4\u00a0 The Strongest Case in Favor of Olive Oil<\/h4>\n

Intellectual honesty requires stating the affirmative case at its strongest before explaining why it falls short of establishing independent efficacy. Several genuine, reproducible findings support olive oil as a component of a heart-healthy pattern.<\/p>\n

Saturated-fat replacement and LDL. <\/strong>Substituting olive oil for butter, lard, or other saturated fats lowers LDL cholesterol and ApoB, and the NHS\/HPFS substitution analyses show meaningfully lower mortality when olive oil displaces animal fats. [1,65] Because LDL\/ApoB is the causal driver of atherosclerosis, this replacement effect is real and clinically useful.<\/p>\n

Blood pressure and endothelial markers. <\/strong>Higher-phenolic olive oils have been associated with modest reductions in blood pressure and improvements in some endothelial and inflammatory markers, and the combined phenolic-oil-plus-red-wine data show that context can even produce acute FMD improvement. [16,65] The EFSA-recognized phenolic claim, whatever its practical caloric cost, rests on a genuine in vitro<\/em> and ex vivo<\/em> antioxidant signal. [22]<\/p>\n

The Mediterranean-pattern signal. <\/strong>Within a whole Mediterranean pattern, EVOO-supplemented diets reduced hard events in both PREDIMED and CORDIOPREV, and reduced carotid plaque progression in CORDIOPREV. [4,8] These are RCT-level outcomes, not merely observational, and they should not be dismissed.<\/p>\n

Why this does not establish independent efficacy. <\/strong>Each of these benefits is explicable without invoking a unique property of the olive-oil lipid. The LDL and mortality effects are replacement effects reproduced by other plant oils; the blood-pressure and marker effects are shared by many polyphenol-rich whole foods delivered at far lower caloric cost; the phenolic antioxidant signal has not translated into a phenol-specific in vivo<\/em> benefit in the cleanest controlled test [24]; and the RCT benefits were measured against weak or animal-protein-rich comparators, within multicomponent patterns, and in trials funded by the olive-oil trade. The affirmative case establishes that olive oil is a good substitute for animal fat and a reasonable part of a plant-rich diet. It does not establish that olive oil, in isolation, is independently cardioprotective\u2014which is the specific claim this review examines.<\/p>\n

2.\u00a0 Postprandial Vascular Dynamics: Isolated Oils versus Whole-Food Fats<\/h3>\n

The acute vascular impact of fat ingestion is seen in the postprandial state\u2014transient endothelial dysfunction, oxidative stress, and inflammatory signaling. The standard index is flow-mediated dilation (FMD) of the brachial artery, a nitric-oxide-dependent response. Consuming isolated dietary oils, including EVOO, consistently produces an acute, significant reduction in FMD. [13]<\/p>\n

In a landmark crossover trial, a single 900-kcal meal containing 50 g of fat from isolated olive oil reduced FMD by ~31% at 3 hours, from a baseline of 14.3 \u00b1 4.2% to 9.9 \u00b1 4.5% (p = 0.008); the decline correlated inversely with the postprandial triglyceride rise (r = \u22120.47, p < 0.05). [13] An earlier draft stated FMD fell \u201cto ~4.5%\u201d; 4.5% is the standard deviation, not the mean. The correct postprandial value is 9.9%, and the trial is Vogel et al. 2000.<\/em><\/p>\n

Comparative studies show divergence by food matrix: a walnut meal preserves or improves FMD while a fat-matched olive-oil meal worsens it. [14] Caveat: the walnut\u2013oil comparison [14] was funded by the California Walnut Commission and one author served on its Scientific Advisory Board. No fully independent head-to-head walnut-versus-oil postprandial trial was identified, so this result should be read as directionally supportive but industry-influenced.<\/em><\/p>\n

An essential caveat applies to this entire section. <\/strong>Only the first step of the postulated chain\u2014that isolated oil acutely reduces FMD\u2014has been directly demonstrated. Whether these transient postprandial endothelial impairments translate into accelerated atherosclerosis and, ultimately, into clinical cardiovascular events has not been shown. That progression is biologically plausible and consistent with the response-to-retention framework, but it remains an inference rather than a demonstrated causal sequence in humans. The postprandial data should therefore be read as a mechanistic signal, not as proof of long-term harm from olive oil.<\/p>\n

2.1\u00a0 Mechanism: Chylomicron Remnants and the Response-to-Retention Model<\/h4>\n

The acute impairment is linked to postprandial lipemia and the response-to-retention model of atherogenesis. [29,33] Rapid absorption of emulsified triacylglycerols from isolated oil produces a surge of chylomicrons; lipoprotein-lipase hydrolysis then yields smaller, atherogenic remnants (<70 nm) that traverse the arterial endothelium via active transcytosis mediated by scavenger receptor class B type 1 (SR-BI) and activin receptor-like kinase 1 (ALK1). [30] Mechanistic (cell\/animal and human-biomarker data), not RCT-grade.<\/em><\/p>\n

In capillaries, this hydrolysis is stabilized by GPIHBP1, which anchors LPL to the luminal surface; larger arteries lack GPIHBP1, so intact remnants interact directly with the arterial wall. [31,32] Retained ApoB-containing remnants bind subendothelial proteoglycans, are oxidized to reactive aldehydes such as 4-hydroxynonenal (4-HNE), and activate NF-\u03baB in endothelium and macrophages, inducing VCAM-1, ICAM-1, and E-selectin; monocytes then adhere, transmigrate, and become foam cells. [33,37,39] Each individual step in this sequence is experimentally supported, but the complete progression from a dietary oil bolus through remnant formation, transcytosis, foam-cell generation, and plaque is inferred by assembling those steps. This integrated pathway remains mechanistic rather than experimentally demonstrated as a continuous sequence in humans.<\/strong><\/p>\n

2.2\u00a0 Nitric Oxide, ADMA, and eNOS Uncoupling<\/h4>\n

Postprandial impairment is largely mediated by reduced nitric-oxide bioavailability. Endothelial NO synthase (eNOS) makes NO from L-arginine; asymmetric dimethylarginine (ADMA) competitively inhibits eNOS and is normally cleared by dimethylarginine dimethylaminohydrolase (DDAH). [40,43] During lipemia, ROS and the lipid aldehyde 4-HNE inhibit DDAH, ADMA accumulates, and eNOS uncouples toward superoxide and peroxynitrite, causing acute endothelial dysfunction. [40,41] This is a mechanistically supported model; the dietary-causal specifics are not established by RCT.<\/p>\n

2.3\u00a0 The Whole-Food Matrix Prevents Postprandial Decline<\/h4>\n

In several controlled studies, whole-food fat sources (fresh avocado, raw walnuts) appear to attenuate or prevent the endothelial impairment seen after isolated oils, rather than reliably eliminating it. [14,15] In a randomized crossover study, substituting fresh Hass avocado for refined carbohydrate improved postprandial FMD and lowered triglyceride-rich lipoproteins versus a fat-matched control. [15] Caveat: avocado postprandial research is frequently funded by the Hass Avocado Board; the specific funding statement should be verified and the result read as industry-adjacent.<\/em> The intact fiber and cell matrix slow gastric emptying and lipase access, smoothing the triglyceride curve, while co-absorbed antioxidants neutralize ROS, preserve DDAH, and maintain eNOS coupling. [44,47]<\/p>\n

The adverse postprandial signature is also modifiable by co-ingested antioxidants. In the Vogel trial, adding vitamins C and E, or a salad with balsamic vinegar, to the olive-oil meal fully prevented the FMD reduction. [13] A separate crossover study reported that combining 50 g of high-phenolic green olive oil with 250 mL of red wine produced a synergistic postprandial FMD improvement sustained for up to two hours (p = 0.002). [16] Funding statement for [16] not retrievable; treat as unverified for independence. Note this result cuts toward \u201cphenolic and whole-food context matters,\u201d not toward isolated-oil benefit.<\/em> The takeaway is that the endothelial injury of isolated oil is context-dependent, not fixed\u2014but the cleanest way to avoid it is to eat fats in whole-food form.<\/p>\n

Table 2.\u00a0 Postprandial Atherogenic Cascade After Isolated-Oil Ingestion (Mechanistic Model)<\/strong><\/h3>\n\n\n\n\n\n\n\n\n\n
Stage<\/strong><\/td>\nKey Mediators<\/strong><\/td>\nMechanism<\/strong><\/td>\nEffect on eNOS \/ Permeability<\/strong><\/td>\n<\/tr>\n<\/thead>\n
1. Lipemia & remnant generation<\/td>\nTriacylglycerols, chylomicrons, LPL<\/td>\nRapid absorption of isolated lipid \u2192 chylomicron surge; LPL hydrolysis \u2192 small dense remnants (<70 nm)<\/td>\nHigh triglycerides impair systemic vascular reactivity<\/td>\n<\/tr>\n
2. Transcytosis & retention<\/td>\nRemnants, SR-BI, ALK1, proteoglycans<\/td>\nRemnants cross the endothelium via SR-BI\/ALK1 and accumulate in the intima<\/td>\nIncreased permeability; ApoB particles bind proteoglycans<\/td>\n<\/tr>\n
3. Oxidative modification<\/td>\nROS, 4-HNE, oxidized remnants<\/td>\nRetained particles are oxidized to cytotoxic aldehydes<\/td>\n4-HNE inhibits DDAH; eNOS uncouples toward superoxide<\/td>\n<\/tr>\n
4. Endothelial activation<\/td>\nNF-\u03baB, VCAM-1, ICAM-1, E-selectin<\/td>\nOxidized lipids activate NF-\u03baB \u2192 adhesion-molecule expression<\/td>\nVascular lining becomes adhesive to leukocytes<\/td>\n<\/tr>\n
5. Monocyte recruitment & foam cells<\/td>\nMonocytes, macrophages, scavenger receptors, IL-6, TNF-\u03b1<\/td>\nAdhered monocytes transmigrate, differentiate, and form foam cells<\/td>\nSustained inflammation; loss of vasodilator tone<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

This cascade is a mechanistic synthesis of cell, animal, and human-biomarker studies [29\u201343]; it is not established as an RCT-grade causal chain in humans.<\/em><\/p>\n

3.\u00a0 Reversal Mechanisms of Whole-Food Plant-Based Diets<\/h3>\n

Where standard low-fat and Mediterranean patterns generally slow progression, strict low-fat WFPB interventions are the only dietary programs that have demonstrated angiographic regression of coronary disease in published intervention studies. That evidence base is small, highly selected, involves several simultaneous lifestyle changes, and has not been independently replicated at the same scale, and it is described here with those limitations explicit rather than as settled superiority. [54]<\/p>\n

Ornish’s Lifestyle Heart Trial (a small RCT, n = 48) combined a ~10%-fat vegetarian diet with no added oils, exercise, stress management, and group support. Quantitative coronary angiography showed regression of average percent-diameter stenosis (40.0% \u2192 37.8% in the intervention group versus progression 42.7% \u2192 46.1% in controls) at 1 year, with further divergence at 5 years. [17,18] LDL cholesterol fell ~37% without lipid-lowering drugs, angina frequency fell markedly, and control patients had roughly twice as many cardiac events by year 5. [18] RCT-grade but small, and the intervention is multi-component, so diet cannot be isolated.<\/em><\/p>\n

Esselstyn’s case series followed 198 patients with established CVD counseled to a strict WFPB diet excluding all added oils; 177\/198 (89%) were adherent. Among adherent patients, one recurrent event occurred (0.6%), versus 13\/21 (62%) among the non-adherent, over a mean 3.7 years. [19] Independent (author-declared no conflicts) but uncontrolled, self-selected, and observational\u2014not RCT-grade. The \u201creversal\u201d claim rests on a small RCT [17,18] plus this uncontrolled cohort; readers should weight it accordingly.<\/em><\/p>\n

3.1\u00a0 Direct Clearance of Circulating ApoB<\/h4>\n

A strict WFPB diet nearly eliminates dietary cholesterol and saturated\/trans fat while supplying soluble fiber and phytosterols, depleting hepatic cholesterol pools, activating sterol regulatory element-binding proteins, and upregulating LDL receptors. [48] Circulating ApoB and LDL-C fall, often below 70 mg\/dL, reducing the gradient that drives lipoprotein entry into the intima and blunting the initiating step of the response-to-retention cascade. [33,35,36] That ApoB is the causal driver is well established from genetic and clinical data. [35,36]<\/p>\n

3.2\u00a0 Restoration of eNOS Activity and NO Bioavailability<\/h4>\n

Eliminating added oils and processed fats lowers triglycerides and prevents ADMA-mediated eNOS uncoupling; leafy greens supply inorganic nitrate reduced to nitrite and then bioactive NO; and abundant polyphenols protect tetrahydrobiopterin (BH4), keeping eNOS coupled. [43,50] These are mechanistically supported pathways rather than hard clinical endpoints.<\/p>\n

3.3\u00a0 The TMAO Pathway<\/h4>\n

Trimethylamine-N-oxide (TMAO), a gut-microbiota-dependent metabolite of dietary carnitine and choline, is associated with accelerated atherosclerosis via effects on macrophage scavenger receptors and reverse cholesterol transport. [52,53] A WFPB shift enriches fiber-fermenting taxa and depletes TMA-producing species, markedly reducing<\/strong> TMAO production. [53] An earlier draft said WFPB \u201centirely abolishes\u201d TMAO; this overreaches. Vegans produce far less TMAO after a carnitine challenge, but endogenous choline metabolism and residual microbial activity mean TMAO is reduced, not eliminated. The claim is corrected to \u201cmarkedly reduces.\u201d<\/em><\/p>\n

3.4\u00a0 Attenuation of Systemic Inflammation<\/h4>\n

Fiber fermentation yields short-chain fatty acids that lower systemic inflammation; WFPB patterns reduce high-sensitivity C-reactive protein and downregulate NF-\u03baB-driven adhesion-molecule expression, shifting the arterial wall from active recruitment toward resolution. [54,62] Effect sizes vary across small trials and should not be over-stated.<\/p>\n

Table 3.\u00a0 Comparative Effects of Three Dietary Patterns<\/strong><\/h3>\n\n\n\n\n\n\n\n\n\n
Parameter<\/strong><\/td>\nLow-Fat Control (30\u201335% fat)<\/strong><\/td>\nMediterranean + EVOO<\/strong><\/td>\nStrict No-Added-Oil WFPB<\/strong><\/td>\n<\/tr>\n<\/thead>\n
LDL-C \/ ApoB<\/td>\nMinimal-to-modest reductions; often fails to lower ApoB to physiological range<\/td>\nModest reductions; LDL-C typically remains 80\u2013100 mg\/dL, leaving residual particle risk<\/td>\nProfound reductions; frequently LDL-C <70 mg\/dL, minimizing intimal entry<\/td>\n<\/tr>\n
Postprandial FMD \/ NO<\/td>\nTransient impairment from refined carbohydrate or saturated fat<\/td>\nAcute FMD reduction (~31% in [13]) unless paired with antioxidants<\/td>\nPostprandial FMD preserved; no added oil, high NO bioavailability<\/td>\n<\/tr>\n
Systemic inflammation (hs-CRP)<\/td>\nMinimal reduction<\/td>\nSignificant reduction reported (industry-linked trials; caveat applies)<\/td>\nSubstantial reduction; NF-\u03baB downregulated<\/td>\n<\/tr>\n
Plaque progression<\/td>\nContinued progression even with statins<\/td>\nDelayed progression; slight IMT regression; recurrent events persist<\/td>\nDocumented angiographic arrest and partial regression (small studies)<\/td>\n<\/tr>\n
Microbial TMAO<\/td>\nHigh; ongoing conversion of carnitine\/choline<\/td>\nVariable; persists with fish, poultry, dairy<\/td>\nMarkedly reduced (not fully abolished)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Estimates for the Mediterranean and WFPB columns derive from trials of differing size and funding independence; see text and Section 4 for caveats.<\/em><\/p>\n

4.\u00a0 Deconstruction of Industry Sponsorship and Nutritional Claims<\/h3>\n

4.1\u00a0 The PREDIMED Retraction and Randomization Failures<\/h4>\n

PREDIMED, published in NEJM in 2013, was the most influential trial supporting the Mediterranean diet and EVOO. [68] Carlisle’s 2017 reanalysis found baseline distributions incompatible with randomization (p < 0.0001). [6] The internal audit found systemic departures from randomization affecting ~1,588 participants (~21% of the cohort): en-masse household assignment at one site, improper use of the randomization table at another, and clinic-level (rather than individual) assignment at a third. [4,5] NEJM retracted the 2013 paper in June 2018 and republished a reanalysis; because it was no longer strictly randomized, its evidence grade fell to that of a quasi-randomized cohort-style intervention. NICE had assessed it at serious risk of bias with low-to-very-low-quality data for individual outcomes. [71]<\/p>\n

4.2\u00a0 CORDIOPREV: A Weak Comparator<\/h4>\n

CORDIOPREV is cited as the premier secondary-prevention trial favoring a Mediterranean over a low-fat diet, but its control arm did not reach a genuine low-fat target (~32% of calories from fat, versus the <30% clinical definition and the <10\u201315% of Ornish and Esselstyn). [8] Saturated fat was near-identical between arms, and the control consumed ~10% more protein\u2014mostly animal-source\u2014while eating fewer whole plant foods. The ~26% MACE reduction may reflect the poor control diet rather than any unique EVOO mechanism. [8]<\/p>\n

4.3\u00a0 Funding Sources and Conflicts of Interest<\/h4>\n

The two major hard-outcome<\/strong> EVOO RCTs discussed here are PREDIMED and CORDIOPREV; numerous smaller RCTs of olive oil on surrogate markers also exist, but none tests hard cardiovascular endpoints independently of the olive-oil trade. PREDIMED, though primarily government-funded, received donated EVOO from Hojiblanca and Patrimonio Comunal Olivarero<\/em>, and donated nuts from the California Walnut Commission and others. [73] Disclosed steering-committee conflicts include Emilio Ros (research grants from and Scientific Advisory Committee membership of the California Walnut Commission) and Jordi Salas-Salvad\u00f3 (grants from and unpaid advisory membership of the International Nut and Dried Fruit Council). [74] An earlier draft attributed International Nut Council funding to M. \u00c1. Mart\u00ednez-Gonz\u00e1lez; that attribution is not supported by the disclosures and has been removed. The verified nut-industry tie belongs to Salas-Salvad\u00f3.<\/em><\/p>\n

CORDIOPREV was supported by the Fundaci\u00f3n Patrimonio Comunal Olivarero<\/em>, an organization dedicated to promoting Spanish olive-oil exports; its very acronym encodes the sponsor’s interest. [76] These systematic ties between a single trade interest and the entire EVOO-efficacy RCT literature justify treating \u201colive oil as superfood\u201d framing with caution. [67,69]<\/p>\n

4.4\u00a0 The Lyon Diet Heart Study: Canola, Not Olive Oil<\/h4>\n

The Lyon Diet Heart Study is often invoked for Mediterranean secondary prevention, reporting roughly a 70% lower all-cause mortality (adjusted risk ratio 0.30; 95% CI 0.11\u20130.82). [27,28] But its supplemental fat was not olive oil: the experimental group received a custom canola-oil-based margarine designed to mimic a Cretan profile, high in alpha-linolenic acid (ALA), with a low omega-6:omega-3 ratio (~2.8). [27,79] Reviewers attributed the mortality benefit substantially to ALA’s anti-arrhythmic and anti-thrombotic effects rather than to olive oil. [78] The choice of canola reflected, in part, Spain’s Toxic Oil Syndrome history, which had made rapeseed-oil trials socially fraught there; this is historical context, not a cardioprotection claim.<\/p>\n

4.5\u00a0 The Polyphenol \u201cHealth Halo\u201d and the Caloric-Efficiency Gap<\/h4>\n

A central marketing claim is EVOO’s biophenol content (hydroxytyrosol, oleuropein, oleocanthal, oleacein). In 2011 the European Food Safety Authority approved a claim that olive-oil polyphenols protect blood lipids from oxidative stress, conditional on \u22655 mg of hydroxytyrosol and its derivatives per 20 g of oil, at 20 g\/day. [22,23]<\/p>\n

But olive oil is a calorically expensive polyphenol vehicle. It is ~100% lipid (~900 kcal\/100 g, ~120 kcal per tablespoon) with negligible fiber, protein, or water-soluble micronutrients. [47] Commodity EVOO often falls below the EFSA threshold, and even premium high-phenolic oils require large lipid loads to deliver a meaningful polyphenol dose, whereas whole plant foods deliver far more polyphenol per calorie. [21,85] The per-food polyphenol values below trace to the Phenol-Explorer database and vary with assay and extraction; the derived gram\/calorie figures are illustrative arithmetic, not measured trial outcomes.<\/em><\/p>\n

Table 4.\u00a0 Caloric Cost of Obtaining 500 mg of Polyphenols by Food Source<\/strong><\/h3>\n\n\n\n\n\n\n\n\n\n\n
Food Source<\/strong><\/td>\nPolyphenols (mg\/100 g)<\/strong><\/td>\nEnergy (kcal\/100 g)<\/strong><\/td>\nMass for 500 mg (g)<\/strong><\/td>\nCaloric cost (kcal)<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Commodity EVOO<\/td>\n~10<\/td>\n900<\/td>\n5,000<\/td>\n45,000<\/td>\n<\/tr>\n
Premium high-phenolic EVOO<\/td>\n~50<\/td>\n900<\/td>\n1,000<\/td>\n9,000<\/td>\n<\/tr>\n
Raw blueberries<\/td>\n560<\/td>\n57<\/td>\n89<\/td>\n51<\/td>\n<\/tr>\n
Black chokeberries<\/td>\n1,022<\/td>\n47<\/td>\n49<\/td>\n23<\/td>\n<\/tr>\n
Dark chocolate (\u226570%)<\/td>\n1,664<\/td>\n598<\/td>\n30<\/td>\n180<\/td>\n<\/tr>\n
Dried cloves<\/td>\n15,188<\/td>\n274<\/td>\n3.3<\/td>\n9<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Polyphenol concentrations from Phenol-Explorer [21,85]; energy values from USDA. Red = calorically expensive polyphenol vehicles; green = efficient whole-food sources. Values should be verified per cell before publication, as Folin assay results vary by method.<\/em><\/p>\n

4.6\u00a0 Do the Phenolics Deliver In Vivo?<\/h4>\n

A controlled crossover trial found that olive oil fortified with polar or non-polar phenolics increased LDL-oxidation lag time by ~8 minutes\u2014but the same increase occurred with the polyphenol-free placebo oil, suggesting a non-specific meal or time effect rather than a unique phenolic benefit. [24] A single trial cannot overturn a field, and other work reports phenol-specific effects; but this relatively independent (Wageningen-led) study raises important questions about the magnitude of the proposed antioxidant mechanism and cautions against treating it as established. [24] Related LDL-oxidation analyses by the same group had Unilever affiliation or International Olive Oil Council funding [89]; the specifically cited 2001 Free Radical Research paper [24] is the cleaner source and is used here.<\/em><\/p>\n

Some industry-linked trials (e.g., EUROLIVE and HDL-function studies) do report phenolic benefits. [49,86] These are cited for completeness but carry funding caveats and should not be read as independent confirmation. [61,63]<\/p>\n

The pharmacology of oleocanthal is real but distinct from clinical cardioprotection: it inhibits COX-1 and COX-2 dose-dependently, like ibuprofen, [25] while the peppery throat sting of high-phenolic oil is mediated by TRPA1 channels restricted to the posterior oropharynx\u2014a sensory phenomenon with no established bearing on cardiovascular outcomes. [26]<\/p>\n

5.\u00a0 Conclusions<\/h3>\n

A critical synthesis indicates that current independent evidence does not demonstrate a clinically meaningful cardioprotective effect of isolated olive oil beyond the replacement of saturated and trans fats. This is a conclusion about the absence of convincing evidence for unique benefit, not positive proof that no such benefit exists. Epidemiological associations are real but are reproduced by other plant oils and are consistent with the displacement of animal fat; MR finds no convincing evidence of a causal MUFA effect and points instead to ApoB. [1,2,10,11]<\/p>\n

Physiologically, isolated EVOO acutely impairs postprandial endothelial function by accelerating chylomicron-remnant generation and retention\u2014an effect that whole-food fat sources appear to attenuate. Whether this transient postprandial impairment translates into long-term atherosclerosis and clinical events has not been demonstrated; it is a plausible mechanistic link, not an established one, and should be presented as such. [13,14,15]<\/p>\n

While EVOO-supplemented diets can slow progression relative to weak comparators, only strict low-fat WFPB patterns excluding added oils have been shown to arrest and partially reverse angiographic coronary disease\u2014though that evidence rests on one small RCT and an uncontrolled cohort and should be described with appropriate humility. [17,18,19]<\/p>\n

Finally, the EVOO efficacy literature is systematically entangled with the olive-oil trade, and its most influential trial was retracted for randomization failure. The strongest evidence in this review\u2014the null comparison against other plant oils, the null MUFA MR, and the null phenolic LDL-oxidation trial\u2014comes from independent or government-funded work. [1,10,24]<\/p>\n

The central evidentiary gap: <\/strong>no large, fully independent RCT of isolated EVOO on hard cardiovascular endpoints exists. Until one does, claims of unique olive-oil cardioprotection should be regarded as unproven, and the reader is entitled to the residual doubt that this review has tried to make explicit throughout.<\/p>\n

References<\/h3>\n

Citations follow IEEE style and are numbered in order of first appearance. Primary peer-reviewed sources (PubMed\/PMC) are used throughout; entries marked \u201cmechanistic\u201d denote preclinical or biomarker-level evidence rather than RCT-grade clinical outcomes. Funding caveats for industry-linked olive-oil sources are noted in the text.<\/em><\/p>\n

    \n
  1. \n
      \n
    1. Guasch-Ferr\u00e9 M, Li Y, Willett WC, et al. Consumption of Olive Oil and Risk of Total and Cause-Specific Mortality Among U.S. Adults. J Am Coll Cardiol<\/em>. 2022;79(2):101-112. doi:10.1016\/j.jacc.2021.10.041<\/li>\n
    2. Guasch-Ferr\u00e9 M, Liu G, Li Y, et al. Olive Oil Consumption and Cardiovascular Risk in U.S. Adults. J Am Coll Cardiol<\/em>. 2020;75(15):1729-1739. doi:10.1016\/j.jacc.2020.02.036<\/li>\n
    3. Xia M, Zhong Y, Peng Y, Qian C. Olive oil consumption and risk of cardiovascular disease and all-cause mortality: A meta-analysis of prospective cohort studies. Front Nutr<\/em>. 2022;9:1041203. Published 2022 Oct 18. doi:10.3389\/fnut.2022.1041203<\/li>\n
    4. Estruch R, Ros E, Salas-Salvad\u00f3 J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med<\/em>. 2018;378(25):e34. doi:10.1056\/NEJMoa1800389<\/li>\n
    5. Estruch R, Ros E, Salas-Salvad\u00f3 J, et al. Retraction and Republication: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;368:1279-90 [retraction of: N Engl J Med. 2013 Apr 4;368(14):1279-90. doi: 10.1056\/NEJMoa1200303.]. N Engl J Med<\/em>. 2018;378(25):2441-2442. doi:10.1056\/NEJMc1806491<\/li>\n
    6. Carlisle JB. Data fabrication and other reasons for non-random sampling in 5087 randomised, controlled trials in anaesthetic and general medical journals. Anaesthesia<\/em>. 2017;72(8):944-952. doi:10.1111\/anae.13938<\/li>\n
    7. Mart\u00ednez-Gonz\u00e1lez M\u00c1, Toledo E, Ar\u00f3s F, et al. Extravirgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED (Prevenci\u00f3n con Dieta Mediterr\u00e1nea) trial. Circulation<\/em>. 2014;130(1):18-26. doi:10.1161\/CIRCULATIONAHA.113.006921<\/li>\n
    8. Delgado-Lista J, Alcala-Diaz JF, Torres-Pe\u00f1a JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet<\/em>. 2022;399(10338):1876-1885. doi:10.1016\/S0140-6736(22)00122-2<\/li>\n
    9. Alcala-Diaz JF, Arenas-de Larriva AP, Torres-Pe\u00f1a JD, et al. A Gene Variation at the ZPR1 Locus (rs964184) Interacts With the Type of Diet to Modulate Postprandial Triglycerides in Patients With Coronary Artery Disease: From the Coronary Diet Intervention With Olive Oil and Cardiovascular Prevention Study. Front Nutr<\/em>. 2022;9:885256. Published 2022 Jun 17. doi:10.3389\/fnut.2022.885256<\/li>\n
    10. Mazidi M, Katsiki N, Shekoohi N, Banach M. Monounsaturated Fatty Acid Levels May Not Affect Cardiovascular Events: Results From a Mendelian Randomization Analysis. Front Nutr<\/em>. 2020;7:123. Published 2020 Sep 2. doi:10.3389\/fnut.2020.00123<\/li>\n
    11. Zagkos L, Dib MJ, Pinto R, et al. Associations of genetically predicted fatty acid levels across the phenome: A mendelian randomisation study. PLoS Med<\/em>. 2022;19(12):e1004141. Published 2022 Dec 29. doi:10.1371\/journal.pmed.1004141<\/li>\n
    12. Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Med<\/em>. 2020;17(3):e1003062. Published 2020 Mar 23. doi:10.1371\/journal.pmed.1003062<\/li>\n
    13. Vogel RA, Corretti MC, Plotnick GD. The postprandial effect of components of the Mediterranean diet on endothelial function. J Am Coll Cardiol<\/em>. 2000;36(5):1455-1460. doi:10.1016\/s0735-1097(00)00896-2<\/li>\n
    14. Cort\u00e9s B, N\u00fa\u00f1ez I, Cof\u00e1n M, et al. Acute effects of high-fat meals enriched with walnuts or olive oil on postprandial endothelial function. J Am Coll Cardiol<\/em>. 2006;48(8):1666-1671. doi:10.1016\/j.jacc.2006.06.057<\/li>\n
    15. Wang L, Bordi PL, Fleming JA, Hill AM, Kris-Etherton PM. Effect of a moderate fat diet with and without avocados on lipoprotein particle number, size and subclasses in overweight and obese adults: a randomized, controlled trial. J Am Heart Assoc<\/em>. 2015;4(1):e001355. Published 2015 Jan 7. doi:10.1161\/JAHA.114.001355<\/li>\n
    16. Karatzi K, Papamichael C, Karatzis E, et al. Postprandial improvement of endothelial function by red wine and olive oil antioxidants: a synergistic effect of components of the Mediterranean diet. J Am Coll Nutr<\/em>. 2008;27(4):448-453. doi:10.1080\/07315724.2008.10719724<\/li>\n
    17. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet<\/em>. 1990;336(8708):129-133. doi:10.1016\/0140-6736(90)91656-u<\/li>\n
    18. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA<\/em>. 1998;280(23):2001-2007. doi:10.1001\/jama.280.23.2001<\/li>\n
    19. Esselstyn CB Jr, Gendy G, Doyle J, Golubic M, Roizen MF. A way to reverse CAD?. J Fam Pract<\/em>. 2014;63(7):356-364b.<\/li>\n
    20. Esselstyn CB Jr. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology). Am J Cardiol<\/em>. 1999;84(3):339-A8. doi:10.1016\/s0002-9149(99)00290-8<\/li>\n
    21. P\u00e9rez-Jim\u00e9nez J, Neveu V, Vos F, Scalbert A. Identification of the 100 richest dietary sources of polyphenols: an application of the Phenol-Explorer database. Eur J Clin Nutr<\/em>. 2010;64 Suppl 3:S112-S120. doi:10.1038\/ejcn.2010.221<\/li>\n
    22. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to polyphenols in olive and protection of LDL particles from oxidative damage (ID 1333, 1638, 1639, 1696, 2865), maintenance of normal blood HDL cholesterol concentrations (ID 1639), maintenance of normal blood pressure (ID 3781), “anti-inflammatory properties” (ID 1882), “contributes to the upper respiratory tract health” (ID 3468), “can help to maintain a normal function of gastrointestinal tract” (3779), and “contributes to body defences against external agents” (ID 3467) pursuant to Article 13(1) of Regulation (EC) No 1924\/2006. EFSA J<\/em>. 2011;9(4):2033. Published 2011 Apr 8. doi:10.2903\/j.efsa.2011.2033<\/li>\n
    23. Commission Regulation (EU) No 432\/2012 of 16 May 2012 establishing a list of permitted health claims made on foods, Off. J. Eur. Union, L 136, pp. 1\u201340, May 2012.<\/a><\/li>\n
    24. Vissers MN, Zock PL, Leenen R, Roodenburg AJ, van Putte KP, Katan MB. Effect of consumption of phenols from olives and extra virgin olive oil on LDL oxidizability in healthy humans. Free Radic Res<\/em>. 2001;35(5):619-629. doi:10.1080\/10715760100301621<\/li>\n
    25. Beauchamp GK, Keast RS, Morel D, et al. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature<\/em>. 2005;437(7055):45-46. doi:10.1038\/437045a<\/li>\n
    26. Peyrot des Gachons C, Uchida K, Bryant B, et al. Unusual pungency from extra-virgin olive oil is attributable to restricted spatial expression of the receptor of oleocanthal. J Neurosci<\/em>. 2011;31(3):999-1009. doi:10.1523\/JNEUROSCI.1374-10.2011<\/li>\n
    27. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet<\/em>. 1994;343(8911):1454-1459. doi:10.1016\/s0140-6736(94)92580-1<\/li>\n
    28. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation<\/em>. 1999;99(6):779-785. doi:10.1161\/01.cir.99.6.779<\/li>\n
    29. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol<\/em>. 1995;15(5):551-561. doi:10.1161\/01.atv.15.5.551<\/li>\n
    30. Bolanle IO, de Liedekerke Beaufort GC, Weinberg PD. Transcytosis of LDL Across Arterial Endothelium: Mechanisms and Therapeutic Targets. Arterioscler Thromb Vasc Biol<\/em>. 2025;45(4):468-480. doi:10.1161\/ATVBAHA.124.321549<\/li>\n
    31. Beigneux AP. GPIHBP1 and the processing of triglyceride-rich lipoproteins. Clin Lipidol<\/em>. 2010;5(4):575-582. doi:10.2217\/clp.10.43<\/li>\n
    32. Goldberg IJ, Bornfeldt KE. Lipids and the endothelium: bidirectional interactions. Curr Atheroscler Rep<\/em>. 2013;15(11):365. doi:10.1007\/s11883-013-0365-1<\/li>\n
    33. Tabas I, Williams KJ, Bor\u00e9n J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation<\/em>. 2007;116(16):1832-1844. doi:10.1161\/CIRCULATIONAHA.106.676890<\/li>\n
    34. Badimon L, Vilahur G. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. Ann N Y Acad Sci<\/em>. 2012;1254:18-32. doi:10.1111\/j.1749-6632.2012.06480.x<\/li>\n
    35. Bor\u00e9n J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J<\/em>. 2020;41(24):2313-2330. doi:10.1093\/eurheartj\/ehz962<\/li>\n
    36. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J<\/em>. 2017;38(32):2459-2472. doi:10.1093\/eurheartj\/ehx144<\/li>\n
    37. Libby P. The changing landscape of atherosclerosis. Nature<\/em>. 2021;592(7855):524-533. doi:10.1038\/s41586-021-03392-8<\/li>\n
    38. van Oostrom AJ, Rabelink TJ, Verseyden C, et al. Activation of leukocytes by postprandial lipemia in healthy volunteers. Atherosclerosis<\/em>. 2004;177(1):175-182. doi:10.1016\/j.atherosclerosis.2004.07.004<\/li>\n
    39. Tsimikas S, Witztum JL. Oxidized phospholipids in cardiovascular disease. Nat Rev Cardiol<\/em>. 2024;21(3):170-191. doi:10.1038\/s41569-023-00937-4<\/li>\n
    40. B\u00f6ger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res<\/em>. 2003;59(4):824-833. doi:10.1016\/s0008-6363(03)00500-5<\/li>\n
    41. B\u00f6ger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med<\/em>. 2006;38(2):126-136. doi:10.1080\/07853890500472151<\/li>\n
    42. Zhao G, Etherton TD, Martin KR, Gillies PJ, West SG, Kris-Etherton PM. Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. Am J Clin Nutr<\/em>. 2007;85(2):385-391. doi:10.1093\/ajcn\/85.2.385<\/li>\n
    43. F\u00f6rstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J<\/em>. 2012;33(7):829-837d. doi:10.1093\/eurheartj\/ehr304<\/li>\n
    44. Kris-Etherton PM, Hecker KD, Bonanome A, et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med<\/em>. 2002;113 Suppl 9B:71S-88S. doi:10.1016\/s0002-9343(01)00995-0<\/li>\n
    45. Ornish D. Avoiding revascularization with lifestyle changes: The Multicenter Lifestyle Demonstration Project. Am J Cardiol<\/em>. 1998;82(10B):72T-76T. doi:10.1016\/s0002-9149(98)00744-9<\/li>\n
    46. Dreher ML, Davenport AJ. Hass avocado composition and potential health effects. Crit Rev Food Sci Nutr<\/em>. 2013;53(7):738-750. doi:10.1080\/10408398.2011.556759<\/li>\n
    47. Rajaram S. The effect of vegetarian diet, plant foods, and phytochemicals on hemostasis and thrombosis. Am J Clin Nutr<\/em>. 2003;78(3 Suppl):552S-558S. doi:10.1093\/ajcn\/78.3.552S<\/li>\n
    48. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA<\/em>. 2003;290(4):502-510. doi:10.1001\/jama.290.4.502<\/li>\n
    49. Covas MI, Nyyss\u00f6nen K, Poulsen HE, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med<\/em>. 2006;145(5):333-341. doi:10.7326\/0003-4819-145-5-200609050-00006<\/li>\n
    50. Kapil V, Khambata RS, Robertson A, Caulfield MJ, Ahluwalia A. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension<\/em>. 2015;65(2):320-327. doi:10.1161\/HYPERTENSIONAHA.114.04675<\/li>\n
    51. Karatzi K, Papamichael C, Karatzis E, et al. Postprandial improvement of endothelial function by red wine and olive oil antioxidants: a synergistic effect of components of the Mediterranean diet. J Am Coll Nutr<\/em>. 2008;27(4):448-453. doi:10.1080\/07315724.2008.10719724<\/li>\n
    52. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med<\/em>. 2013;368(17):1575-1584. doi:10.1056\/NEJMoa1109400<\/li>\n
    53. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med<\/em>. 2013;19(5):576-585. doi:10.1038\/nm.3145<\/li>\n
    54. Tuso P, Stoll SR, Li WW. A plant-based diet, atherogenesis, and coronary artery disease prevention. Perm J<\/em>. 2015;19(1):62-67. doi:10.7812\/TPP\/14-036<\/li>\n
    55. Esselstyn CB. A plant-based diet and coronary artery disease: a mandate for effective therapy. J Geriatr Cardiol<\/em>. 2017;14(5):317-320. doi:10.11909\/j.issn.1671-5411.2017.05.004<\/li>\n
    56. Esselstyn CB Jr, Ellis SG, Medendorp SV, Crowe TD. A strategy to arrest and reverse coronary artery disease: a 5-year longitudinal study of a single physician’s practice. J Fam Pract<\/em>. 1995;41(6):560-568.<\/li>\n
    57. Fern\u00e1ndez-Rodr\u00edguez R, Bizzozero-Peroni B, D\u00edaz-Go\u00f1i V, et al. Plant-based meat alternatives and cardiometabolic health: a systematic review and meta-analysis. Am J Clin Nutr<\/em>. 2025;121(2):274-283. doi:10.1016\/j.ajcnut.2024.12.002<\/li>\n
    58. Campbell TC. A plant-based diet and animal protein: questioning dietary fat and considering animal protein as the main cause of heart disease. J Geriatr Cardiol<\/em>. 2017;14(5):331-337. doi:10.11909\/j.issn.1671-5411.2017.05.011<\/li>\n
    59. Dinu M, Abbate R, Gensini GF, Casini A, Sofi F. Vegetarian, vegan diets and multiple health outcomes: A systematic review with meta-analysis of observational studies. Crit Rev Food Sci Nutr<\/em>. 2017;57(17):3640-3649. doi:10.1080\/10408398.2016.1138447<\/li>\n
    60. Weech M, Altowaijri H, Mayneris-Perxachs J, et al. Replacement of dietary saturated fat with unsaturated fats increases numbers of circulating endothelial progenitor cells and decreases numbers of microparticles: findings from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study. Am J Clin Nutr<\/em>. 2018;107(6):876-882. doi:10.1093\/ajcn\/nqy018<\/li>\n
    61. M.-I. Covas et al., \u201cMinor components of olive oil: Evidence to date of health benefits in humans,\u201d Nutr. Rev., vol. 64, no. 10 pt 2, pp. S20\u2013S30, 2006 (industry-linked review; funding caveat in text).<\/a><\/li>\n
    62. Kahleova H, Levin S, Barnard N. Cardio-Metabolic Benefits of Plant-Based Diets. Nutrients<\/em>. 2017;9(8):848. Published 2017 Aug 9. doi:10.3390\/nu9080848<\/li>\n
    63. Estruch R. Anti-inflammatory effects of the Mediterranean diet: the experience of the PREDIMED study. Proc Nutr Soc<\/em>. 2010;69(3):333-340. doi:10.1017\/S0029665110001539<\/li>\n
    64. Nishi SK, Paz-Graniel I, Ni J, et al. Effect of nut consumption on blood lipids: An updated systematic review and meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis<\/em>. 2025;35(5):103771. doi:10.1016\/j.numecd.2024.10.009<\/li>\n
    65. Schwingshackl L, Hoffmann G. Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies. Lipids Health Dis<\/em>. 2014;13:154. Published 2014 Oct 1. doi:10.1186\/1476-511X-13-154<\/li>\n
    66. Ros E, Mart\u00ednez-Gonz\u00e1lez MA, Estruch R, et al. Mediterranean diet and cardiovascular health: Teachings of the PREDIMED study. Adv Nutr<\/em>. 2014;5(3):330S-6S. Published 2014 May 14. doi:10.3945\/an.113.005389<\/li>\n
    67. Nestle M. Food Industry Funding of Nutrition Research: The Relevance of History for Current Debates. JAMA Intern Med<\/em>. 2016;176(11):1685-1686. doi:10.1001\/jamainternmed.2016.5400<\/li>\n
    68. Estruch R, Ros E, Salas-Salvad\u00f3 J, et al. Retraction and Republication: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;368:1279-90 [retraction of: N Engl J Med. 2013 Apr 4;368(14):1279-90. doi: 10.1056\/NEJMoa1200303.]. N Engl J Med<\/em>. 2018;378(25):2441-2442. doi:10.1056\/NEJMc1806491<\/li>\n
    69. Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med<\/em>. 2013;173(7):580-581. doi:10.1001\/jamainternmed.2013.4190<\/li>\n
    70. A.-M. Chang et al., commentary on PREDIMED randomization irregularities, republished analysis context, N. Engl. J. Med., 2018 (see [4], [5]).<\/a><\/li>\n
    71. Evidence review for dietary cholesterol strategies: Cardiovascular disease: risk assessment and reduction, including lipid modification<\/em>. London: National Institute for Health and Care Excellence (NICE); May 2023.<\/a><\/li>\n
    72. Alcala-Diaz JF, Arenas-de Larriva AP, Torres-Pe\u00f1a JD, et al. A Gene Variation at the ZPR1 Locus (rs964184) Interacts With the Type of Diet to Modulate Postprandial Triglycerides in Patients With Coronary Artery Disease: From the Coronary Diet Intervention With Olive Oil and Cardiovascular Prevention Study. Front Nutr<\/em>. 2022;9:885256. Published 2022 Jun 17. doi:10.3389\/fnut.2022.885256<\/li>\n
    73. PREDIMED Study Investigators, \u201cFunding and food-industry donations disclosure,\u201d in [4] supplementary appendix, N. Engl. J. Med., 2018.<\/a><\/li>\n
    74. Conflict-of-interest disclosures, PREDIMED steering committee, in [4] supplementary appendix (E. Ros: California Walnut Commission; J. Salas-Salvad\u00f3: International Nut and Dried Fruit Council), N. Engl. J. Med., 2018.<\/a><\/li>\n
    75. Estruch R, Ros E, Salas-Salvad\u00f3 J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med<\/em>. 2018;378(25):e34. doi:10.1056\/NEJMoa1800389<\/li>\n
    76. Fundaci\u00f3n Patrimonio Comunal Olivarero, funding acknowledgment, in CORDIOPREV [8], Lancet, 2022.<\/a><\/li>\n
    77. de Lorgeril M, Salen P. The Mediterranean diet in secondary prevention of coronary heart disease. Clin Invest Med<\/em>. 2006;29(3):154-158.<\/li>\n
    78. Visioli F, Galli C. Alpha-linolenic acid and cardiovascular disease. Am J Clin Nutr<\/em>. 2002;75(6):1121-1122. doi:10.1093\/ajcn\/75.6.1121<\/li>\n
    79. de Lorgeril M, Salen P. Modified Cretan Mediterranean diet in the prevention of coronary heart disease and cancer. World Rev Nutr Diet<\/em>. 2000;87:1-23.<\/li>\n
    80. Hu FB. The Mediterranean diet and mortality–olive oil and beyond. N Engl J Med<\/em>. 2003;348(26):2595-2596. doi:10.1056\/NEJMp030069<\/li>\n
    81. EFSA Panel on Nutrition, Novel Foods and Food allergens (NDA), Turck D, Bohn T, et al. Olive oil polyphenols and the maintenance of normal HDL-cholesterol concentrations: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924\/2006. EFSA J<\/em>. 2025;23(5):e9372. Published 2025 May 2. doi:10.2903\/j.efsa.2025.9372<\/li>\n
    82. Fabiani R. Anti-cancer properties of olive oil secoiridoid phenols: a systematic review of in vivo studies. Food Funct<\/em>. 2016;7(10):4145-4159. doi:10.1039\/c6fo00958a<\/li>\n
    83. Owen RW, Giacosa A, Hull WE, et al. Olive-oil consumption and health: the possible role of antioxidants. Lancet Oncol<\/em>. 2000;1:107-112. doi:10.1016\/s1470-2045(00)00015-2<\/li>\n
    84. Crespo MC, Tom\u00e9-Carneiro J, D\u00e1valos A, Visioli F. Pharma-Nutritional Properties of Olive Oil Phenols. Transfer of New Findings to Human Nutrition. Foods<\/em>. 2018;7(6):90. Published 2018 Jun 11. doi:10.3390\/foods7060090<\/li>\n
    85. Neveu V, Perez-Jim\u00e9nez J, Vos F, et al. Phenol-Explorer: an online comprehensive database on polyphenol contents in foods. Database (Oxford)<\/em>. 2010;2010:bap024. doi:10.1093\/database\/bap024<\/li>\n
    86. Hern\u00e1ez \u00c1, Fern\u00e1ndez-Castillejo S, Farr\u00e0s M, et al. Olive oil polyphenols enhance high-density lipoprotein function in humans: a randomized controlled trial. Arterioscler Thromb Vasc Biol<\/em>. 2014;34(9):2115-2119. doi:10.1161\/ATVBAHA.114.303374<\/li>\n
    87. Key TJ, Fraser GE, Thorogood M, et al. Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies. Am J Clin Nutr<\/em>. 1999;70(3 Suppl):516S-524S. doi:10.1093\/ajcn\/70.3.516s<\/li>\n
    88. Yeung AWK. Food Composition Databases (FCDBs): A Bibliometric Analysis. Nutrients<\/em>. 2023;15(16):3548. Published 2023 Aug 11. doi:10.3390\/nu15163548<\/li>\n
    89. Casta\u00f1er O, Covas MI, Khymenets O, et al. Protection of LDL from oxidation by olive oil polyphenols is associated with a downregulation of CD40-ligand expression and its downstream products in vivo in humans. Am J Clin Nutr<\/em>. 2012;95(5):1238-1244. doi:10.3945\/ajcn.111.029207<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Distinguez les preuves scientifiques des mythes nutritionnels gr\u00e2ce \u00e0 une analyse critique de l'huile d'olive et des maladies cardiovasculaires.<\/p>","protected":false},"author":16,"featured_media":11942,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[216,223,224,254],"tags":[],"class_list":["post-11936","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-diet-and-nutrition","category-plaque-arteries-and-disease","category-regression-and-reversal","category-specific-foods"],"acf":[],"yoast_head":"\nIs Olive Oil Actually Healthy? - The Premiere Heart Health Education Platform<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curingheartdisease.com\/fr\/lhuile-dolive-est-elle-vraiment-bonne-pour-la-sante\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Is Olive Oil Actually Healthy? - The Premiere Heart Health Education Platform\" \/>\n<meta property=\"og:description\" content=\"Separate scientific evidence from nutrition myths with a critical review of olive oil and cardiovascular disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curingheartdisease.com\/fr\/lhuile-dolive-est-elle-vraiment-bonne-pour-la-sante\/\" \/>\n<meta property=\"og:site_name\" content=\"The Premiere Heart Health Education Platform\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/curingheartdisease\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-10T15:06:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-25T13:18:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/07\/post-image-79.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Peter Megdal PhD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:site\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Peter Megdal PhD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"32 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/\"},\"author\":{\"name\":\"Peter Megdal PhD\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\"},\"headline\":\"Is Olive Oil Actually Healthy?\",\"datePublished\":\"2026-07-10T15:06:14+00:00\",\"dateModified\":\"2026-08-25T13:18:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/\"},\"wordCount\":7193,\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/post-image-79.jpg\",\"articleSection\":[\"Diet and Nutrition\",\"Plaque, Arteries and Disease\",\"Regression and Reversal\",\"Specific Foods\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/\",\"name\":\"Is Olive Oil Actually Healthy? - The Premiere Heart Health Education Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/post-image-79.jpg\",\"datePublished\":\"2026-07-10T15:06:14+00:00\",\"dateModified\":\"2026-08-25T13:18:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/post-image-79.jpg\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/post-image-79.jpg\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/is-olive-oil-actually-healthy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Is Olive Oil Actually Healthy?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"name\":\"The Premiere Heart Health Education Platform\",\"description\":\"To make available to the public the state of the art information on how to reverse heart disease. This is an evidence-based organization utilizing the best available science, including diet, exercise drugs, and other resources to best fight this disease.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curingheartdisease.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\",\"name\":\"Curing Heart Disease, LLC\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"width\":512,\"height\":512,\"caption\":\"Curing Heart Disease, LLC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/curingheartdisease\",\"https:\\\/\\\/x.com\\\/RMHDInc\",\"https:\\\/\\\/www.instagram.com\\\/rmhdinc\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm8dh9c_D5RfJL7Z1f-yY4w\"],\"description\":\"Curing Heart Disease, LLC is an independent cardiovascular health education organization that publishes evidence-based articles, videos, podcasts, and educational tools about cardiovascular disease prevention, lipid science, nutrition, exercise, and related health topics.\",\"founder\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"foundingPerson\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"knowsAbout\":[\"Cardiovascular health\",\"Cardiovascular disease prevention\",\"Heart disease education\",\"Nutrition\",\"Exercise\",\"Lipid science\",\"Atherosclerosis\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\",\"givenName\":\"Peter\",\"familyName\":\"Megdal\",\"honorificSuffix\":\"PhD\",\"jobTitle\":\"Nutrition Researcher and Cardiovascular Health Educator\",\"description\":\"Peter Megdal, PhD, is a nutrition researcher, cardiovascular health educator, published researcher, and longtime competitive cyclist. He earned a PhD in nutrition from the University of Massachusetts and publishes evidence-based cardiovascular health education through Curing Heart Disease.\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\"},\"worksFor\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"affiliation\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"alumniOf\":{\"@type\":\"CollegeOrUniversity\",\"name\":\"University of Massachusetts\"},\"knowsAbout\":[\"Nutrition\",\"Cardiovascular health education\",\"Cardiovascular disease prevention\",\"Lipid science\",\"Exercise physiology\",\"Scientific research\"],\"sameAs\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/author\\\/peter-megdal\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/peter-megdal-56075a2\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'huile d'olive est-elle vraiment bonne pour la sant\u00e9 ? - La premi\u00e8re plateforme d'\u00e9ducation sur la sant\u00e9 cardiaque","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curingheartdisease.com\/fr\/lhuile-dolive-est-elle-vraiment-bonne-pour-la-sante\/","og_locale":"fr_FR","og_type":"article","og_title":"Is Olive Oil Actually Healthy? - The Premiere Heart Health Education Platform","og_description":"Separate scientific evidence from nutrition myths with a critical review of olive oil and cardiovascular disease.","og_url":"https:\/\/www.curingheartdisease.com\/fr\/lhuile-dolive-est-elle-vraiment-bonne-pour-la-sante\/","og_site_name":"The Premiere Heart Health Education Platform","article_publisher":"https:\/\/www.facebook.com\/curingheartdisease","article_published_time":"2026-07-10T15:06:14+00:00","article_modified_time":"2026-08-25T13:18:46+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/07\/post-image-79.jpg","type":"image\/jpeg"}],"author":"Peter Megdal PhD","twitter_card":"summary_large_image","twitter_creator":"@RMHDInc","twitter_site":"@RMHDInc","twitter_misc":{"\u00c9crit par":"Peter Megdal PhD","Dur\u00e9e de lecture estim\u00e9e":"32 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/#article","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/"},"author":{"name":"Peter Megdal PhD","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53"},"headline":"Is Olive Oil Actually Healthy?","datePublished":"2026-07-10T15:06:14+00:00","dateModified":"2026-08-25T13:18:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/"},"wordCount":7193,"publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/07\/post-image-79.jpg","articleSection":["Diet and Nutrition","Plaque, Arteries and Disease","Regression and Reversal","Specific Foods"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/","url":"https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/","name":"L'huile d'olive est-elle vraiment bonne pour la sant\u00e9 ? - La premi\u00e8re plateforme d'\u00e9ducation sur la sant\u00e9 cardiaque","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/#primaryimage"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/07\/post-image-79.jpg","datePublished":"2026-07-10T15:06:14+00:00","dateModified":"2026-08-25T13:18:46+00:00","breadcrumb":{"@id":"https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/#primaryimage","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/07\/post-image-79.jpg","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/07\/post-image-79.jpg","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.curingheartdisease.com\/is-olive-oil-actually-healthy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curingheartdisease.com\/"},{"@type":"ListItem","position":2,"name":"Is Olive Oil Actually Healthy?"}]},{"@type":"WebSite","@id":"https:\/\/www.curingheartdisease.com\/#website","url":"https:\/\/www.curingheartdisease.com\/","name":"La premi\u00e8re plateforme d'\u00e9ducation sur la sant\u00e9 cardiaque","description":"Mettre \u00e0 la disposition du public les informations les plus r\u00e9centes sur la mani\u00e8re d'inverser les maladies cardiaques. Il s'agit d'une organisation fond\u00e9e sur des donn\u00e9es probantes qui utilise la meilleure science disponible, notamment le r\u00e9gime alimentaire, l'exercice physique, les m\u00e9dicaments et d'autres ressources pour lutter au mieux contre cette maladie.","publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curingheartdisease.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.curingheartdisease.com\/#organization","name":"Curing Heart Disease, LLC","url":"https:\/\/www.curingheartdisease.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","width":512,"height":512,"caption":"Curing Heart Disease, LLC"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/curingheartdisease","https:\/\/x.com\/RMHDInc","https:\/\/www.instagram.com\/rmhdinc\/","https:\/\/www.youtube.com\/channel\/UCm8dh9c_D5RfJL7Z1f-yY4w"],"description":"Curing Heart Disease, LLC est une organisation ind\u00e9pendante d'\u00e9ducation \u00e0 la sant\u00e9 cardiovasculaire qui publie des articles, des vid\u00e9os, des podcasts et des outils \u00e9ducatifs fond\u00e9s sur des donn\u00e9es probantes concernant la pr\u00e9vention des maladies cardiovasculaires, la science des lipides, la nutrition, l'exercice physique et des sujets de sant\u00e9 connexes.","founder":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"foundingPerson":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"knowsAbout":["Cardiovascular health","Cardiovascular disease prevention","Heart disease education","Nutrition","Exercise","Lipid science","Atherosclerosis"]},{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD","url":"https:\/\/www.curingheartdisease.com\/peters-story\/","givenName":"Peter","familyName":"Megdal","honorificSuffix":"PhD","jobTitle":"Nutrition Researcher and Cardiovascular Health Educator","description":"Peter Megdal, PhD est chercheur en nutrition, formateur en sant\u00e9 cardiovasculaire, auteur de publications scientifiques et cycliste de comp\u00e9tition de longue date. Titulaire d'un doctorat en nutrition de l'universit\u00e9 du Massachusetts, il diffuse des informations fond\u00e9es sur des donn\u00e9es scientifiques en mati\u00e8re de sant\u00e9 cardiovasculaire via le site \u00ab Curing Heart Disease \u00bb.","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/peters-story\/"},"worksFor":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"affiliation":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"alumniOf":{"@type":"CollegeOrUniversity","name":"University of Massachusetts"},"knowsAbout":["Nutrition","Cardiovascular health education","Cardiovascular disease prevention","Lipid science","Exercise physiology","Scientific research"],"sameAs":["https:\/\/www.curingheartdisease.com\/author\/peter-megdal\/","https:\/\/www.linkedin.com\/in\/peter-megdal-56075a2\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/posts\/11936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/comments?post=11936"}],"version-history":[{"count":6,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/posts\/11936\/revisions"}],"predecessor-version":[{"id":12959,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/posts\/11936\/revisions\/12959"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/media\/11942"}],"wp:attachment":[{"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/media?parent=11936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/categories?post=11936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/fr\/wp-json\/wp\/v2\/tags?post=11936"}],"curies":[{"name":"Bien jou\u00e9","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}